Cerebrospinal fluid total tau as a marker of Alzheimer's disease intensity.

Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift


OBJECTIVES: The aim of this longitudinal study was to test the hypothesis that CSF biomarkers in AD patients also may be forward-looking measures that are associated not only with the degree and profile of cognitive impairment but also with changes in cognition over time. METHODS: Here, we assessed the association of CSF Abeta42, T-tau and P-tau with neuropsychological scores of disease severity, as well as the rate of disease progression, in 142 patients with Alzheimer's disease. All patients were part of a 3-year prospective longitudinal treatment study. RESULTS: A more rapid progress in MMSE score reduction was seen in AD patients with T-tau levels higher than the upper quartile (800 ng/L) compared with Alzheimer's disease patients with lower T-tau levels (p = 0.008). We also found that individuals with T-tau > 800 ng/L performed worse in total scores and especially in memory and orientation when assessed with MMSE and ADAS cog than patients with T-tau <800 ng/L. Similar results were obtained for P-tau. No associations were seen between Abeta42 and cognitive scores or disease progression. DISCUSSION: These findings support the hypothesis that increased levels of T-tau reflect the intensity of the disease and are associated with a more rapid disease progress. Copyright (c) 2009 John Wiley & Sons, Ltd.


Enheter & grupper

Ämnesklassifikation (UKÄ) – OBLIGATORISK

  • Klinisk medicin
  • Neurologi
Sidor (från-till)403-410
TidskriftInternational Journal of Geriatric Psychiatry
StatusPublished - 2010
Peer review utfördJa

Relaterad forskningsoutput

Stubendorff, K., 2014, Clinical Memory Research Unit, Lund University. 93 s.

Forskningsoutput: AvhandlingDoktorsavhandling (sammanläggning)

Visa alla (1)